The price-to-earnings ratio for Dexcom Inc (NASDAQ: DXCM) is 44.74x, which is above its average ratio. Moreover, the 36-month beta value for DXCM is 1.18. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 8 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for DXCM is 395.36M and currently, short sellers hold a 2.42% of that float. On October 22, 2024, DXCM’s average trading volume was 5.85M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DXCM) stock’s latest price update
Dexcom Inc (NASDAQ: DXCM) has experienced a rise in its stock price by 0.32 compared to its previous closing price of 72.38. However, the company has seen a gain of 4.96% in its stock price over the last five trading days. accesswire.com reported 2024-10-21 that NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=109074&wire=1 or contact Joseph E. Levi, Esq.
DXCM’s Market Performance
Dexcom Inc (DXCM) has experienced a 4.96% rise in stock performance for the past week, with a 3.10% rise in the past month, and a -35.24% drop in the past quarter. The volatility ratio for the week is 3.12%, and the volatility levels for the past 30 days are at 2.61% for DXCM. The simple moving average for the past 20 days is 5.90% for DXCM’s stock, with a -32.63% simple moving average for the past 200 days.
Analysts’ Opinion of DXCM
Many brokerage firms have already submitted their reports for DXCM stocks, with Robert W. Baird repeating the rating for DXCM by listing it as a “Neutral.” The predicted price for DXCM in the upcoming period, according to Robert W. Baird is $80 based on the research report published on July 26, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see DXCM reach a price target of $75, previously predicting the price at $145. The rating they have provided for DXCM stocks is “Neutral” according to the report published on July 26th, 2024.
Redburn Atlantic gave a rating of “Neutral” to DXCM, setting the target price at $130 in the report published on May 30th of the current year.
DXCM Trading at 3.68% from the 50-Day Moving Average
After a stumble in the market that brought DXCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.87% of loss for the given period.
Volatility was left at 2.61%, however, over the last 30 days, the volatility rate increased by 3.12%, as shares surge +4.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.09% upper at present.
During the last 5 trading sessions, DXCM rose by +4.96%, which changed the moving average for the period of 200-days by -40.40% in comparison to the 20-day moving average, which settled at $68.57. In addition, Dexcom Inc saw -41.49% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DXCM starting from Heller Bridgette P, who sale 1,000 shares at the price of $70.00 back on Sep 16 ’24. After this action, Heller Bridgette P now owns 24,349 shares of Dexcom Inc, valued at $70,000 using the latest closing price.
Heller Bridgette P, the Director of Dexcom Inc, proposed sale 1,000 shares at $70.00 during a trade that took place back on Sep 16 ’24, which means that Heller Bridgette P is holding shares at $70,000 based on the most recent closing price.
Stock Fundamentals for DXCM
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.63 for the gross margin
The net margin for Dexcom Inc stands at 0.17. The total capital return value is set at 0.13. Equity return is now at value 29.41, with 9.79 for asset returns.
Based on Dexcom Inc (DXCM), the company’s capital structure generated 0.5 points at debt to capital in total, while cash flow to debt ratio is standing at 0.36. The debt to equity ratio resting at 1.01. The interest coverage ratio of the stock is 35.49.
Currently, EBITDA for the company is 916.7 million with net debt to EBITDA at 1.82. When we switch over and look at the enterprise to sales, we see a ratio of 7.82. The receivables turnover for the company is 3.94for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.82.
Conclusion
To wrap up, the performance of Dexcom Inc (DXCM) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
